PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial
May 06, 2021 03:30 ET
|
Peptomyc S.L.
BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) -- Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research...
F-star Therapeutics to Present at Upcoming Investor Conferences
March 04, 2021 08:00 ET
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
Cannabics Pharmaceuticals Inc. CEO talks with Uptick Newswire’s Stock Day Podcast About Cancer Research in the Cannabinoid Sector
November 06, 2018 08:30 ET
|
Cannabics Pharmaceuticals Inc.
PHOENIX, Ariz., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) (the “Company”) is a U.S public company that is developing a platform which leverages novel...
Yun Yen, MD, PhD and Winson (Sze Chun) Ho, MD Join Lixte Biotechnology’s Board of Directors
August 08, 2018 11:30 ET
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today the appointments of two new members to the Board of Directors of Lixte: Yun Yen,...